A5013902375- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Mechanisms and Therapy
- Cancer, Lipids, and Metabolism
- Liver Disease and Transplantation
- MicroRNA in disease regulation
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Circular RNAs in diseases
- Liver Diseases and Immunity
- Metabolism, Diabetes, and Cancer
- Galectins and Cancer Biology
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Esophageal and GI Pathology
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal Tumor Research and Treatment
- Systemic Lupus Erythematosus Research
- Cancer-related Molecular Pathways
- Renal cell carcinoma treatment
- Pancreatitis Pathology and Treatment
Kagawa University
2016-2025
Nippon Medical School
2023
Kagawa University Hospital
2021-2023
Toshima Hospital
2017-2021
GTx (United States)
2020
Hudson Institute
2020
Takamatsu University
2013
Recent studies suggest that metformin, which is commonly used as an oral anti-hyperglycemic agent of the biguanide family, may reduce cancer risk and improve prognosis, but mechanisms by metformin affects various cancers, including gastric cancer, remains unknown. The goal present study was to evaluate effects on human cell proliferation in vitro vivo microRNAs (miRNA) associated with antitumor effect metformin. We MKN1, MKN45, MKN74 lines cells. Athymic nude mice bearing xenograft tumors...
A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy.We carried out a retrospective analysis prospectively collected data consecutive patients with advanced HCC, treated atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers 4 countries (Italy, Japan, Republic Korea, and UK). The primary endpoint was overall survival (OS) bevacizumab versus lenvatinib. Secondary endpoints were progression-free (PFS) OS PFS...
Abstract Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy have yet to be reported. Aim This retrospective clinical study aimed elucidate early responses Atez/Bev. Methods From September 2020 April 2021, 171 u‐HCC patients undergoing Atez/Bev were enrolled (BCLC stage A:B:C:D = 5:68:96:2). Of those, 75 had no prior history of systemic treatment. Relative and...
Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of treated with Atez/Bev, especially CP-A and -B cases.From September 2020 March 2022, 457 u-HCC Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B 427:30, score [CPS] 5:6:7:8:9 271:156:21:8:1). Therapeutic response was evaluated using RECIST ver.1.1. Clinical features...
To investigate whether neutrophil-to-lymphocyte ratio (NLR) can predict outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated atezolizumab plus bevacizumab (Atez/Bev).A total of 249 HCC Atez/Bev were included. We analyzed survival and discontinuation this therapy cohort.Cumulative overall at 2, 4, 6, 8 months was 97.6%, 94.9%, 88.9%, 82.8%, respectively. Cumulative differed significantly between low (<3.0) versus high (≥3.0) NLR (P = 0.001). Conversely, cumulative...
The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.A total 1381 had PD at therapy. 917 received as treatment, 464 bevacizumab first-line.49.6% a therapy without any statistical difference in overall survival (OS) between (20.6months) (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After first-line, there wasn't...
Introduction: Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is important clinical issue. The present study aimed to elucidate the potential lenvatinib as a second-line option after Atez/Bev failure. Methods: From 2020 2022, 101 patients who received were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-A:B:C:D = 1:35:61:4), while 29 treated with another molecular targeting agent (MTA)...
Background/Aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use tumor markers as biomarkers monitoring treatment response is necessary. This study aimed to elucidate changes positive rates 3 available Japan, including alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and lens culinaris agglutinin-reactive AFP (AFP-L3) uHCC...
Surgical resection remains the only curative treatment for combined hepatocellular-cholangiocarcinoma; however, systemic therapy is primary option unresectable cases. This multicenter retrospective study aimed to assess efficacy of hepatocellular-cholangiocarcinoma. Twenty-one patients with histologically confirmed or clinically diagnosed hepatocellular-cholangiocarcinoma who received were included. First-line regimens consisted lenvatinib (n=14) and atezolizumab plus bevacizumab (n=7) their...
Metformin is a commonly used oral anti-hyperglycemic agent of the biguanide family. Recent studies suggest that metformin may reduce cancer risk and improve prognosis. However, antitumor mechanism in several types cancers, including hepatocellular carcinoma (HCC), has not been elucidated. The goal present study was to evaluate effects on HCC cell proliferation vitro vivo, microRNAs (miRNAs) associated with effect vitro. We lines Alex, HLE Huh7, normal hepatocytes human cells. In an vivo...
Galectin-9, a soluble β-galactoside-binding animal lectin, evokes apoptosis in various human cancer cell lines. The galectin-9 antitumor effect against hepatocellular carcinoma (HCC) is, however, unknown. We investigated whether suppresses HCC growth vitro and vivo. assessed the of on cells by conducting WST-8 assay xenograft model analysis Galectin-9-induced was evaluated FACS ELISA TUNEL stain Cell cycle alteration profiled FACS. Caspases were colorimetry. MicroRNAs related to effects...
<b><i>Introduction:</i></b> Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is considered a safe and minimally invasive procedure. We previously reported that the mortality complication rates RFA were 0.038% (5/13,283 patients) 3.54% (579 complications/16,346 procedures), respectively, from 1999 to 2010 (previous period). In this study, we investigated clinical criteria 2011 2015 (recent <b><i>Methods:</i></b> Data collected 25...
It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed evaluate the therapeutic efficacy of lenvatinib in fatty liver disease (NAFLD)/NASH-related unresectable-HCC (u-HCC). Five hundred thirty u-HCC Child-Pugh A were enrolled, and divided into NAFLD/NASH (n = 103) Viral/Alcohol 427) groups. Clinical features compared a retrospective manner....
A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first-line therapy for unresectable hepatocellular carcinoma (u-HCC) in regard to progression-free survival (PFS) overall (OS) has not been reported. We aimed elucidate which those initial u-HCC greater prognostic impact on PFS OS affected patients, retrospectively.From 2020 January 2022, 251 (Child-Pugh A, ECOG PS 0/1, BCLC-B/C) treated were enrolled (Atez/Bev-group, n =...
The present study focused on the association of early bevacizumab (Bev) interruption with clinical outcome atezolizumab plus bevacizumab.This retrospective included 239 patients advanced hepatocellular carcinoma receiving atezolizumab/Bev from September 2020 to June 2021 at 16 different institutions in Japan. We conducted a 9-week landmark analysis investigate Bev due adverse events therapeutic efficacy.The median age was 73.0 (68.0-80.0) years old, 195 (81.6%) men. objective response rate...
The present study focused on Geriatric Nutritional Risk Index (GNRI), which is based bodyweight and serum albumin, known as an easy-to-use nutritional assessment tool in clinical settings, to elucidate the prognostic predictive ability of GNRI patients treated with atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC).A total 525 HCC Atez/Bev, their classification unsuitable status curative treatments and/or transarterial catheter chemoembolization, were enrolled...